Botox Spasticity denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for botox spasticity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies OnabotulinumtoxinA (Botox) for Spasticity as "Not FDA-Approved" — and Why This Denial Is Highly Contestable

OnabotulinumtoxinA (Botox) holds FDA approval specifically for spasticity in adult upper and lower limbs. A denial citing "not FDA-approved" for this indication is almost always based on a coding or documentation mismatch rather than a correct reading of the drug's regulatory status. Common triggers include: a diagnosis code that maps to a pediatric or off-label application not listed in Humana's policy; a claim submitted under a body region the policy has not explicitly listed as covered; or an administrative error in how the claim was coded by the provider's billing team.

Because the FDA approval is a matter of public record — documented in the prescribing label — this type of denial is one of the strongest to appeal. An IRO reviewer is unlikely to uphold a denial that conflicts with the FDA label.

## Federal Appeal Framework

ACA §2719 provides internal appeal rights followed by independent external review for most non-grandfathered plans. ERISA §503 governs self-funded employer plans with a full-and-fair review standard. The external review window runs approximately four months from the final internal denial. If the patient's functional status is declining, request expedited review — a decision must be rendered within 72 hours.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter and identify the exact reason code and the specific indication or diagnosis code Humana flagged. 2. Verify the diagnosis and procedure codes submitted by the provider. If a coding error is identified, request a corrected claim before or alongside the appeal. 3. Pull the current FDA-approved prescribing information for Botox directly from FDA.gov or the manufacturer. Attach the relevant indication section to the appeal. 4. File the Level 1 internal appeal by the deadline on the denial notice. 5. If denied, proceed to Level 2 or IRO external review.

## Documentation to Gather

• FDA prescribing label: the approved Indications and Usage section confirming adult upper/lower limb spasticity — obtained from FDA.gov or directly from AbbVie/Allergan
• Diagnosis confirmation: specialist chart note with ICD-10 code matching an FDA-approved spasticity indication
• Procedure and billing codes: CPT and HCPCS codes submitted; confirm J-code alignment with the product dispensed
• Clinical severity: spasticity assessments and functional impairment documentation from the chart
• Prescriber medical-necessity letter affirming FDA-approved indication and directly refuting the not-approved classification
• Professional society guideline reference: name the applicable guideline organization (AAN, AAPM&R) that endorses botulinum toxin for this indication

## Criteria-Mapping Structure

Address the specific basis for Humana's not-FDA-approved finding:

| Humana's Stated Basis | Your Rebuttal | |---|---| | Indication not FDA-approved | [Cite FDA label section — adult upper/lower limb spasticity, approval date] | | Diagnosis code mismatch | [Corrected ICD-10 code and chart note confirming it] | | Procedure/billing code error (if applicable) | [Corrected CPT/HCPCS with provider attestation] | | Not supported by professional guidelines | [Reference AAN or AAPM&R guideline organization] |

Attach a copy of the relevant FDA label pages to the appeal packet. This converts an abstract argument into a document-supported rebuttal that is difficult for a reviewer to dismiss.